CAMBRIDGE, Mass.--(BUSINESS WIRE)--Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Jeff Goater as its Chief Business Officer.
Mr. Goater comes to Surface Oncology with over 15 years of strategy, business development and financial experience in the biotechnology industry. He joins Surface from Voyager Therapeutics, where he was Chief Financial Officer. At Voyager, Mr. Goater was a member of the founding leadership team and oversaw business development, finance, investor relations, corporate communications, operations, and IT. He led the company through multiple strategic collaborations and financings, including an $845 million partnership with Sanofi Genzyme and a $73 million IPO. Prior to Voyager, he spent nearly a decade on Wall Street, most recently as a Managing Director at Evercore Partners where he advised on more than $100 billion in strategic transactions. In addition, he brings several years of biotechnology business development leadership experience.
“Surface has made incredible progress over the past two years building a robust product pipeline, forging a transformative collaboration with Novartis, and assembling a great team,” said Mr. Goater. “I am thrilled to be onboard as Surface prepares to advance its lead program targeting CD47 into the clinic this year and I look forward to contributing to the company’s continued success as it strives to bring innovative immunotherapies to patients in need.”
“Jeff has a wide range of relevant business, finance, and strategy leadership experience in the biotech sector,” said Detlev Biniszkiewicz, PhD, President and CEO of Surface Oncology. “His experience will be vital to execute on our growth strategy. Surface Oncology has a strong and innovative pipeline that has the potential to bring cures to patients suffering from cancer.”
ABOUT SURFACE ONCOLOGY
In order to re-activate patients’ immune responses to cancer, Surface Oncology is developing next-generation immunotherapies targeting the tumor microenvironment. Our broad attack has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We are committed to advancing our diverse pipeline of immunotherapies, including our fully human CD47 antibody SRF231 and CD73 antibody programs, to bring more cures to patients who do not benefit from existing cancer treatments.
To accomplish this, Surface’s world-class team is working with scientific founders, our network of leading academic collaborators, and a robust scientific platform integrating tumor immunology, antibody characterization, and translational science.
Headquartered in the heart of Cambridge’s Kendall Square, Surface was founded by Atlas Venture and financed by an industry-leading syndicate of investors. In 2016, Surface entered into a global strategic collaboration with Novartis to bring four next-generation immunotherapies to patients.
